Sido Muncul stock keeps High Dividend status in Indeks52

PT Industri Jamu dan Farmasi Sido Muncul Tbk retained its position in the High Dividend category of the Tempo-IDNFinancials 52 Index after the annual evaluation was announced on Thursday, November 5, 2026. IDNFinancials reported that the classification reflects the company's record of earnings and shareholder distributions.

Profit and dividends support ranking

Sido Muncul generated net profit of IDR 1.22 trillion in 2025, an increase of 4.97 percent from the previous year. Cash dividends for the latest financial year totaled IDR 1.09 trillion, corresponding to a dividend yield of 5.80 percent according to the evaluation report.

The recognition keeps dividend income in focus for investors following the Indonesian consumer-healthcare company. It does not by itself change the company's earnings outlook, but it highlights the role of shareholder distributions alongside operating performance.

Herbal products anchor operations

Sido Muncul produces modern herbal medicines, traditional remedies, supplements, food and beverages, and pharmaceutical products. Its investor-relations materials describe production facilities for herbal medicine, powdered and ready-to-drink beverages, supplements, and pharmaceuticals, with operations centered in Indonesia. The company therefore combines a traditional herbal franchise with consumer products and pharmaceutical manufacturing rather than relying on a single product category.

Sido Muncul at a glance

• Company: PT Industri Jamu dan Farmasi Sido Muncul Tbk
• ISIN: ID1000130305
• IDX ticker: SIDO
• Business: Herbal medicines, supplements, food and beverages, and pharmaceutical products
• 2025 net profit: IDR 1.22 trillion
• Latest financial-year cash dividends: IDR 1.09 trillion

Indonesia's broader equity market remains the relevant regional backdrop for the company; investors can follow Current market reports.

Further coverage is available in More news and analyses on Sido Muncul stock.